TARID – Thymic Abnormalities in Rare Immunological Diseases
CONSORTIUM AGREEMENT
for a project under the European Joint Programme on Rare Diseases (EJP RD)
Coordinator: University of Helsinki
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
CONTENTS
1 Definitions ................................................................................................................................................................... 4
2 Purpose ....................................................................................................................................................................... 5
3 Duration ...................................................................................................................................................................... 6
3.1 Entry into force ................................................................................................................................................. 6
3.2 Duration and termination ................................................................................................................................. 6
3.3 Survival of rights and obligations ...................................................................................................................... 6
4 Responsibilities of Parties ........................................................................................................................................... 6
4.1 General principles ............................................................................................................................................. 6
4.2 Breach ............................................................................................................................................................... 8
4.3 Involvement of third parties ............................................................................................................................. 8
5 Liability towards each other ....................................................................................................................................... 9
5.1 No warranties .................................................................................................................................................... 9
5.2 Limitations of contractual liability ..................................................................................................................... 9
5.3 Damage caused to third parties ........................................................................................................................ 9
5.4 Force Majeure ................................................................................................................................................... 9
6 Governance structure ................................................................................................................................................. 9
6.1 General structure .............................................................................................................................................. 9
6.2 General Assembly .............................................................................................................................................. 9
6.3 Coordinator ..................................................................................................................................................... 12
7 Financial provisions................................................................................................................................................... 12
7.1 Funding Principles ........................................................................................................................................... 12
7.2 Justifying Costs ................................................................................................................................................ 12
7.3 Financial Consequences of the termination of the participation of a Party ................................................... 12
8 Results....................................................................................................................................................................... 13
8.1 Ownership of Results ...................................................................................................................................... 13
8.2 Joint Ownership .............................................................................................................................................. 13
8.3 Protection of Results ....................................................................................................................................... 14
8.4 Transfer of Results .......................................................................................................................................... 14
8.5 Dissemination .................................................................................................................................................. 14
9 Access Rights............................................................................................................................................................. 15
9.1 Background included ....................................................................................................................................... 15
9.2 General Principles ........................................................................................................................................... 15
9.3 Access Rights for implementation ................................................................................................................... 16
9.4 Access Rights for Exploitation ......................................................................................................................... 16
9.5 Access Rights for Affiliated Entities ................................................................................................................. 16
9.6 Additional Access Rights.................................................................................................................................. 17
9.7 Access Rights for Parties entering or leaving the consortium ......................................................................... 17
9.8 Specific Provisions for Access Rights to Software ........................................................................................... 17
10 Non-disclosure of information............................................................................................................................. 17
10.1 Confidential Information ................................................................................................................................. 17
10.2 Obligations of the Recipient ............................................................................................................................ 17
10.3 Exceptions to Confidentiality obligations ........................................................................................................ 18
10.4 Duty to Notify .................................................................................................................................................. 18
10.5 Personal Data ............................................................................................................ Erreur ! Signet non défini.
1 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
11 Miscellaneous ...................................................................................................................................................... 18
11.1 Attachments, inconsistencies and severability ............................................................................................... 18
11.2 No representation, partnership or agency ...................................................................................................... 19
11.3 Notices and other communication .................................................................................................................. 19
11.4 Assignment and amendments ......................................................................................................................... 19
2 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
THIS CONSORTIUM AGREEMENT is made between
1. The University of Helsinki (“Coordinator” or “UH”)
Department: Translational Immunology Research Program
Address: Haartmaninkatu 3, P.O. Box 21, FI-00014 University of Helsinki
Represented by Research Program Unit Director Henna Tyynismaa
2. Hospital District of Helsinki and Uusimaa (“HUS”)
Department: HUS Diagnostic Center, Helsinki University Hospital
Address: P.O. box 720, 00029 HUS, Finland
Represented by Research Director Anne Pitkäranta
3. Université de Nantes, a scientific, cultural and professional establishment registered under the laws of France
established at 1 Quai de Tourville, po box: 13522, 44035 , Nantes CEDEX 1, France
Acting in its own name and on behalf of INSERM, in the frame of their joint research unit: « Centre de
Recherche en Transplantation et Immunologie” (“UN” U1064)
Represented by its president, Olivier LABOUX
4. University of Tartu (“UT”)
Department: Institute of Biomedicine and Translational Medicine
Address: Ülikooli 18, 50090, Tartu, Estonia
Represented by Head of Grant Office Taivo Raud
5. Instituto de Medicina Molecular João Lobo Antunes (“iMM”)
Department: N/A
Address: Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal
Represented by Executive Director Maria M. Mota
hereinafter each individually a “Party” and jointly the “Parties”
relating to the Project entitled “Thymic Abnormalities in Rare Immunological Diseases”, in short “TARID”
hereinafter referred to as the “Project”,
and is made on the date of the last signature or on March 1st, 2020 whichever is earlier, hereinafter referred
to as the Effective Date.
WHEREAS:
A. The Parties submitted a proposal to the European Joint Programme on Rare Diseases (“EJP RD”) for the
Project, which has been scientifically approved by a review committee.
B. The Parties wish to collaborate to carry out the Project as envisaged in the proposal submitted in
response to the EJP RD Joint Transnational Call 2019.
C. The Parties are funded by the relevant national or regional funding organization(s) of their country and
shall enter into an agreement with their respective national funding organizations.
D. Some Parties wish to specify or supplement binding commitments among themselves in addition to – but
not in conflict with - the provisions of their respective grant award Letters.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
3 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
1 DEFINITIONS
Words beginning with a capital letter shall have the meaning defined herein.
“Access Rights” means rights to use Results or Background under the terms and conditions laid down in this
Consortium Agreement.
“Background” shall be limited to any data, know-how, material or information, whatever its form or nature,
including any intellectual property rights that is held by the Parties before their accession to the Consortium
Agreement, and which is Needed for performing the Project or for Exploitation of the Results.
The Parties’ Background at the Effective Date of the Consortium Agreement is specified in Attachment 2 hereto.
“Consortium Agreement” means this agreement.
“Consortium Plan” means the description of the Project in the application submitted to the EJP RD Joint
Transnational Call 2019 and the financial plan contained therein, which may be updated by the General
Assembly.
“Coordinator” means UH. UH has appointed Eliisa Kekäläinen to represent it in its duties as a Coordinator, in
case of absence or impediment preventing the appointed person from performing her duties, UH will appoint
another person.
“Personal Data” means any information relating to an identified or identifiable natural person (‘data subject’);
an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to
an identifier such as a name, an identification number, location data, an online identifier or to one or more
factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that
natural person.
“Defaulting Party” means a Party that the General Assembly has identified to be in breach of this Consortium
Agreement.
“Dissemination” means disclosing Results to the public by appropriate means (other than those resulting from
protecting or exploiting the Results), including in scientific publications (in any medium).
“Exploitation” means the direct or indirect utilization of Results, in particular through transfer or licensing by
- using them in further contractual research activities with industrial third parties, or
- by developing, creating and marketing a product or process, or
- for creating and providing a service, or
- using them in standardization activities.
“Fair and reasonable conditions” means appropriate conditions, including possible financial terms or royalty-
free conditions, taking into account the specific circumstances of the request for access, for example the actual
or potential value of the Results or Background to which access is requested and/or the scope, duration or other
characteristics of the exploitation envisaged
“Force Majeure” means any situation or event that:
- prevents a Party from fulfilling its obligations under the Consortium Agreement,
- was unforeseeable, exceptional situation and beyond the Party’s control,
- was not due to error or at least negligence on part of the Party (or on the part of third parties involved
in the Project), and
- proves to be inevitable in spite of exercising all due diligence
- and cannot be overcome despite reasonable endeavors.
The following cannot be invoked as Force Majeure:
- any default of a service, defect in equipment or material or delays in making them available, unless
they stem directly from a relevant case of Force Majeure,
- labour disputes or strikes, or
- financial difficulties.
4 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
Any situation constituting Force Majeure must be formally notified to the other Parties without delay, stating
the nature, likely duration and foreseeable effects.
The Parties must immediately take all the necessary steps to limit any damage due to Force Majeure and do their
best to resume implementation of the Project as soon as possible. The Party prevented by Force Majeure from
fulfilling its obligations under the Consortium Agreement cannot be considered in breach of them.
“Intellectual Property” shall mean any and all forms of intellectual property protection, including without
limitation, patents, utility models, trademarks, copyright, design rights and unregistered design rights,
confidential know how as well as applications for intellectual property protection.
“Material” Material means any non-human material and data related thereto which is either owned/stored by
a Party before the commencement of the Project or during the Project but outside the Project or
collected/generated by a Party in the context and during the execution of the Project which may be transferred
between the Parties for the performance of the Project in the frame of a Material Transfer Agreement. Each
transfer needs to be accompanied by a transmission sheet, an example is set forth in Attachment 5.
"National Funding Organization (NFO)" means the relevant national or regional funding bodies which provide
funding to the Parties for their participation in the Project.
“Needed” means:
(a) for the implementation of the Project: Access Rights are Needed if, without the grant of such Access Rights,
carrying out the tasks assigned to the recipient Party would be impossible, significantly delayed, or require
significant additional financial or human resources.
(b) for Exploitation of own Results: Access Rights are Needed if, without the grant of such Access Rights, the
Exploitation of own Results would be technically or legally impossible.
“Results” means any tangible or intangible output of the Project such as data, knowledge or information,
whatever its form or nature, whether it can be protected or not, that is generated in the Project, as well as any
rights attached to it, including intellectual property rights.
“Software” means sequences of instructions to carry out a process in, or convertible into, a form executable by
a computer and fixed in any tangible medium of expression.
2 PURPOSE
The purpose of this Consortium Agreement is to establish a consortium between the Parties to conduct the
Project, and to specify with respect to the Project the relationship among the Parties, in particular concerning
the organization of the work between the Parties, the management of the Project and the rights and obligations
of the Parties concerning inter alia liability, Access Rights and dispute resolution.
Scientific contact persons for the Project:
UH, Eliisa Kekäläinen (
[email protected]) and T. Petteri Arstila (
[email protected])
HUS, Eliisa Kekäläinen (
[email protected])
UN, Carole Guillonneau (
[email protected]) and Matthieu Giraud (
[email protected])
UT, Pärt Peterson (
[email protected])
iMM, Luís Graça (
[email protected])
Each Party ensures that this Consortium Agreement is in line with the regulations and conditions of its respective
individual grant award letter including the terms and conditions of the individual grant award letter of its
respective NFO. In case of conflict, the Parties concerned shall be entitled to request that a valid and practicable
provision be negotiated that fulfils the purpose of the original provision.
5 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
3 DURATION
3.1 Entry into force
An entity becomes a Party to this Consortium Agreement upon signature of this Consortium Agreement by a duly
authorised representative.
This Consortium Agreement shall have effect from the Effective Date identified at the beginning of this
Consortium Agreement.
3.2 Duration and termination
The term of this Agreement is from 01th March 2020 until 30th June 2023 (i.e. corresponding to the term for
grants of the EJP RD Joint Transnational Call 2019).
However, this Consortium Agreement or the participation of one or more Parties to it may be terminated earlier
in accordance with the terms of this Consortium Agreement. If the NFO terminates the grant or a Party’s
participation, this Consortium Agreement shall automatically terminate in respect of the affected Party/ies,
subject to the provisions surviving the expiration or termination under Article 3.3 of this Consortium Agreement.
3.3 Survival of rights and obligations
3.3.1 The provisions relating to Access Rights, Dissemination and confidentiality, for the time period mentioned
therein, as well as for liability, applicable law and settlement of disputes shall survive the expiration or
termination of this Consortium Agreement.
3.3.2 Termination shall not affect any rights or obligations of a Party leaving the consortium incurred prior to the date
of termination, unless otherwise agreed between the General Assembly and the leaving Party. This includes the
obligation to provide all input, deliverables and documents for the period of its participation.
4 RESPONSIBILITIES OF PARTIES
4.1 General principles
4.1.1 Each Party undertakes to take part in the efficient implementation of the Project, and to cooperate, perform and
fulfil, promptly and on time, all of its obligations this Consortium Agreement as may be reasonably required from
it and in a manner of good faith.
4.1.2 Each Party undertakes to notify promptly, in accordance with the governance structure of the Project, any
significant information, fact, problem or delay likely to affect the Project.
4.1.3 Each Party shall promptly provide all information reasonably required by the General Assembly or by the
Coordinator to carry out its tasks.
4.1.4 Each Party shall take reasonable measures to ensure the accuracy of any information or materials it supplies to
the other Parties.
When a Party (the “Provider”) sends biological material to another Party (the “Recipient”) in respect of the
Project, a bilateral material and data transfer agreement (MDTA), shall be concluded between such Parties to
specify the conditions applying to such transfer of Material or data. The Material or data shall only be used for
the purpose of the Project and only for as long as is necessary for that purpose. The Recipient will be entirely
responsible for the use of the biological material and/or data and the Provider shall have no obligation or liability
for the material, except for gross negligence or willful misconduct. Material and/or data provided in the
performance of the Project shall remain the property of the Provider. The Recipient shall not be entitled to
transfer the Material or data to any third party (including another Party) without the Provider’s prior written
consent.
Each Party is responsible for ensuring that the MDTA is adapted to the relevant situation and that it complies
with this Consortium Agreement and all applicable rules, laws or regulations in the Parties´ place and country.
6 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
.
In the event that one Party (the “Supplier”) transfers Materials and/or Data to another Party (the “Recipient”),
the Recipient Party undertakes that all or part of such Material and/or Data:
(a) Will only be used for the sole purposes of conducting the Project and only for as long as it is necessary for
this purpose, to the exclusion of any other application, in particular for commercial purposes. No express
or implied licenses or other rights are provided to the Recipient under any patents, patent applications,
trade secrets or other proprietary rights of the Supplier, other than the right to use the Material and/or
Data for conducting the Project;
(b) Will not be disclosed, distributed, transferred or licensed to a third party, for any purpose whatsoever,
without prior written authorization from the Supplier and in accordance with the
authorization/declaration necessary for the transfer;
(c) Will not be used on human subjects, particularly for clinical trials or diagnostic purposes, except as defined
in the Consortium Plan and necessary for the implementation of the Project;
(d) Will be used and stored in accordance with the applicable legal and regulatory provisions, notably the
provisions relating to the protection of the personal data and to medical secrecy. In particular, the
Recipient ensures that it has obtained any necessary authorizations and/or opinions and taken appropriate
measures for the storage and use of the concerned Material and/or Data;
(e) Will be returned to the Supplier in the event of the withdrawal of the consent or the exercise of the
opposition right of the donor which would be communicated by the Supplier to the Recipient;
(f) Will no longer be used and will be returned to the Supplier (or destroy, at the Supplier’s discretion) upon
request and/or in the event of the termination of this Consortium Agreement and/or upon the expiry
thereof and without any copy being made thereof; and
(g) Will be used and stored exclusively on the premises of the Recipient within the performance of the Project
and by scientists working on the premises of the Recipient or under its direct responsibility and with the
same degree of security that it applies to its own Data.
Except as specifically agreed otherwise among the relevant Parties in respect of a particular transfer of Material
and/or Data upon a separate Material/Data Transfer Agreement, the Recipient acknowledges that the Material
and/or Data is a research tool supplied “as is", without any guarantee of any kind, whether express or implied,
particularly as regards the preservation, use or manipulation of the Material and/or Data, the fitness and
sufficiency or the possibility of using them for a given purpose, or infringement of third party’s rights. In
particular, the Data are supplied without any guarantee of any kind, whether express or implied, particularly as
regards the possibility of using it for a given purpose. However, Supplier shall use reasonable endeavors to ensure
the accuracy of any information it provides.
Any Party which is aware of, or becomes aware of, a safety risk, which originates from the Material, shall inform
the other Party without delay and provide it with all information in its possession concerning such risks. The
Supplier recognizes that it is authorized to transfer the Material and/or Data to the Recipient, and in particular
for the purpose of the Project and that the Material and/or the Data were collected in compliance with the
applicable laws and regulatory provisions, and notably with the 2018 reform of EU data protection rules, GDPR.
The Supplier will communicate to the Recipient all the information at its disposal relating to the preservation and
use of the Materials.
In any case, the data and/or Material collected by a Party under the Project shall not be transferred to another
Party or to a subcontractor or to any third party before any identifying information has been removed by coding
or by rendering it anonymous in accordance with all applicable laws and regulations.
Any transfer and/or access to Material and/or data shall be evidenced by the execution of a transmission sheet,
a template of which is included in Attachment 5, and which may be completed by concerned Parties (notably
with regard to the reimbursement and shipping costs) in accordance with this Consortium Agreement.
7 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
As regards human biological materials and/or Personnal Data, Appendix 6 is the MTA template that shall be used
for material and/or data owned by HUS, it may be used also by other Parties subject to amendment as needed
by the concerned Parties.
Each Party using such templates is responsible for ensuring that it is completed correctly, adapted to the relevant
situation and that it complies with all applicable rules, laws or regulations, and with the Consortium Agreement,
especially concerning the human biological samples importation and exportation and data protection.
4.1.5 Each Party shall ensure that its work on the Project complies fully with all applicable local, government and
international laws, regulations and guidelines as applicable in the Party´s place and country which are effective
during the period of the Project, including those governing health and safety, data protection, and where
relevant, the use of human or animal subjects and good clinical practice. In this regard, each Party shall maintain
the confidentiality, in accordance with the applicable laws, regulations and guidelines in the Party´s place and
country, of all samples and data relating to the use of human subjects, which is created or used in the course of
the Project.
4.1.6 Each Party shall secure all necessary approvals from the relevant research ethics committees before undertaking
any part of the Project requiring ethics committee approval and shall, if required, obtain properly signed
informed consent and acknowledgement forms from any human subjects, or their legal guardians, who they will
involve in the Project. Where any part of the Project takes place in a hospital, the Party involved shall first obtain
all necessary approvals, indemnities and agreements from that hospital.
4.2 Data Protection
Each Party shall confirm that they comply with the EJP RD ethical requirements (Attachment 7).
For the avoidance of doubt, Personal data shall always be treated as confidential, and shall be protected with an
adequate level of safety and confidentiality, subject to any applicable legal, regulatory or contractual
requirements.
When collecting (Data Controller) and processing personal data (Data Processor), the Parties agree to take
appropriate measures in order to preserve the confidentiality of personal Data.
4.3 Breach
In the event that a responsible Consortium Body identifies a breach by a Party of its obligations under this
Consortium Agreement (e.g. improper implementation of the Project), the Coordinator or, if the Coordinator is
in breach of its obligations, the Party appointed by the General Assembly, will give formal notice to such Party
requiring that the breach will be remedied within 30 calendar days from the date of receipt of the written notice
by the Party.
If the breach is substantial and is not remedied within that period or is not capable of remedy, the General
Assembly may decide to declare the Party to be a Defaulting Party and to decide on the consequences thereof
which may include termination of its participation in the Project.
4.4 Involvement of third parties
A Party that enters into a subcontract or otherwise involves third parties in the Project remains responsible for
carrying out its relevant part of the Project and for such third party’s compliance with the provisions of this
Consortium Agreement and of the respective NFO funding decision. It has to ensure that the involvement of third
parties does not affect the rights and obligations of the other Parties under this Consortium Agreement and the
Grant Agreement.
8 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
5 LIABILITY TOWARDS EACH OTHER
5.1 No warranties
In respect of any information or materials (incl. Results and Background) supplied by one Party to another under
the Project, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness
for purpose nor as to the absence of any infringement of any proprietary rights of third parties.
Therefore,
- the recipient Party shall in all cases be entirely and solely liable for the use to which it puts such
information and materials, and
- no Party granting Access Rights shall be liable in case of infringement of proprietary rights of a third
party resulting from any other Party (or its Affiliated Entities) exercising its Access Rights.
5.2 Limitations of contractual liability
No Party shall be responsible to any other Party for any indirect or consequential loss or similar damage such as,
but not limited to, loss of profit, loss of revenue or loss of contracts, provided such damage was not caused by a
willful act or by a breach of confidentiality.
For any remaining contractual liability, a Party’s aggregate liability towards the other Parties collectively shall be
limited to once the Party’s share of the total costs of the Project as identified in the Consortium Plan, provided
such damage was not caused by a willful act or gross negligence.
5.3 Damage caused to third parties
Each Party shall be solely liable for any loss, damage or injury to third parties resulting from the performance of
the said Party’s obligations by it or on its behalf under this Consortium Agreement or from its use of Results or
Background.
5.4 Force Majeure
No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its
obligations under the Consortium Agreement by Force Majeure.
Each Party will notify the competent Consortium Bodies of any Force Majeure without undue delay. If the
consequences of Force Majeure for the Project are not overcome within 6 weeks after such notification, the
transfer of tasks - if any - shall be decided by the competent Consortium Bodies.
6 GOVERNANCE STRUCTURE
6.1 General structure
The organizational structure of the consortium shall comprise the following Consortium Bodies:
General Assembly as the ultimate decision-making body of the consortium
The Coordinator is the legal entity acting as the intermediary between the Parties and the EJP RD. The
Coordinator shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as described in this
Consortium Agreement.
6.2 General Assembly
6.2.1 Members
The General Assembly shall consist of one representative of each Party, except for University of Helsinki and
CRTI/UN that both have two representatives (hereinafter “Member”).
9 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
Each Assembly Member shall be deemed to be duly authorized to deliberate, negotiate and decide on all matters
listed in Section 6.2.7 of this Consortium Agreement, subject to confirmation as need be by the legal
representative of each Party.
The Coordinator shall chair all meetings of the General Assembly, unless decided otherwise in a meeting of the
General Assembly.
The Parties agree to abide by all decisions of the General Assembly. This does not prevent the Parties to submit
a dispute to resolution in accordance with the provisions of Settlement of disputes in Section 11.8.
6.2.2 Representation in meetings
Any Member:
- should be present or represented at any meeting;
- may appoint a substitute or a proxy to attend and vote at any meeting;
- shall participate in a cooperative manner in the meetings.
6.2.3 Preparation and organization of meetings
Convening meetings:
The chairperson shall convene ordinary meetings of the General Assembly at least once a year, and shall also
convene extraordinary meetings at any time upon written request of any Member.
Notice of a meeting:
The chairperson shall give notice in writing of a meeting to each Member as soon as possible and no later than
20 calendar days preceding an ordinary meeting and 14 calendar days preceding an extraordinary meeting.
Sending the agenda:
The chairperson shall send each Member a written original agenda no later than 14 calendar days preceding an
ordinary meeting, or 10 calendar days before an extraordinary meeting.
Adding agenda items:
Any agenda item requiring a decision by the Members must be identified as such on the agenda.
Any Member may add an item to the original agenda by written notification to all of the other Members no later
than 7 calendar days preceding the meeting.
During a meeting of the General Assembly the Members present or represented can unanimously agree to add
a new item to the original agenda.
Other procedural matters:
Decisions will only be binding once the relevant part of the minutes has been accepted according to Section 6.3.6
of this Consortium Agreement.
Any decision may also be taken without a meeting if the chairperson circulates to all Members a written
document which is then signed by the defined majority of Members (see Section 6.2.4). Such document shall
include the deadline for responses that cannot be inferior to 15 calendar days. Decisions taken without a meeting
shall be considered as accepted if, within the period set out in article 6.2.5, no Member has sent an objection in
writing to the chairperson. The decisions will be binding after the chairperson sends to all Members a written
notification of this acceptance.
Meetings of the General Assembly may also be held by teleconference or other telecommunication means, such
as Skype, Teams, etc.
6.2.4 Voting rules and quorum
The General Assembly shall not deliberate and decide validly unless two-thirds (2/3) of its Members, including
the Coordinator, are present or represented (quorum).
10 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
If the quorum is not reached, the chairperson shall convene another ordinary meeting within 15 calendar days.
If in this meeting the quorum is not reached once more, the chairperson shall convene an extraordinary meeting
which shall be entitled to decide even if less than the quorum of Members are present or represented.
Each Member shall have one vote.
Defaulting Parties may not vote.
Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast.
6.2.5 Veto rights
A Member which can show that its own work, time for performance, costs, liabilities, intellectual property rights
or other legitimate interests would be severely affected by a decision of the General Assembly may exercise a
veto with respect to the corresponding decision or relevant part of the decision.
When the decision is foreseen on the original agenda, a Member may veto such a decision during the meeting
only. When a decision has been taken on a new item added to the agenda before or during the meeting, a
Member may veto such decision during the meeting and within 15 days after the draft minutes of the meeting
are sent.
When a decision has been taken without a meeting a Member may veto such decision within 15 calendar days
after written notification by the chairperson of the outcome of the vote.
In case of exercise of veto, the Members shall make every effort to resolve the matter which occasioned the veto
to the general satisfaction of all Members.
A Party may not veto decisions relating to its identification as a Defaulting Party. The Defaulting Party may not
veto decisions relating to its participation and termination in the consortium or the consequences thereof.
A Party requesting to leave the consortium may not veto decisions relating thereto.
6.2.6 Minutes of meetings
The chairperson shall produce written minutes of each meeting which shall be the formal record of all decisions
taken. The chairperson shall send draft minutes to all Members within 10 calendar days of the meeting.
The minutes shall be considered as accepted if, within 15 calendar days from sending, no Member has sent an
objection in writing to the chairperson with respect to the accuracy of the draft of the minutes.
The chairperson shall send the accepted minutes to all the Members. The Coordinator shall safeguard them. If
requested, the Coordinator shall provide authenticated duplicates to Parties.
6.2.7 Decisions
The General Assembly shall be free to act on its own initiative to formulate proposals and take decisions in
accordance with the procedures set out herein.
The following decisions shall be taken by the General Assembly:
Content, finances and intellectual property rights
- Changes to the Consortium Plan
- Modifications to Attachment 1 (Background Included)
- Additions to Attachment 3 (List of Third Parties for simplified transfer according to Section 8.4)
- Additions to Attachment 4 (Identified Affiliated Entities)
Evolution of the consortium
- Entry of a new Party to the consortium and approval of the settlement on the conditions of the
accession of such a new Party
- Withdrawal of a Party from the consortium and the approval of the settlement on the conditions of
the withdrawal
- Identification of a breach by a Party of its obligations under this Consortium Agreement
11 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
- Declaration of a Party to be a Defaulting Party
- Remedies to be performed by a Defaulting Party
- Termination of a Defaulting Party’s participation in the consortium and measures relating thereto
- Proposal to the EJP RD for a change of the Coordinator
- Proposal to the EJP RD for suspension of all or part of the Project
- Proposal to the EJP RD for termination of the Project and the Consortium Agreement
In the case of abolished tasks as a result of a decision of the General Assembly, Members shall endeavor to
rearrange the tasks of the Parties concerned. Such rearrangement shall take into consideration the legitimate
commitments taken prior to the decisions, which cannot be cancelled.
6.3 Coordinator
6.3.1 In addition to the general tasks assigned to the Coordinator at Section 6.1, the Coordinator shall be responsible
for:
- monitoring compliance by the Parties with their obligations
- keeping the address list of Members and other contact persons updated and available
- collecting, reviewing, and submitting information on the progress of the Project and reports and other
deliverables to the EJP RD
- preparing the meetings, proposing decisions and preparing the agenda of the General Assembly
meetings, chairing the meetings, preparing the minutes of the meetings and monitoring the
implementation of decisions taken at meetings
- transmitting promptly documents and information connected with the Project
- providing, upon request, the Parties with official copies or originals of documents which are in the
sole possession of the Coordinator when such copies or originals are necessary for the Parties to
present claims.
6.3.2 If one or more of the Parties is late in submission of any project deliverable, the Coordinator may nevertheless
submit the other parties’ project deliverables and all other documents required to the EJP RD in time.
6.3.3 If the Coordinator fails in its coordination tasks, the General Assembly may propose to the EJP RD to change the
Coordinator.
6.3.4 The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other Party
or of the consortium
6.3.5 The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement.
7 FINANCIAL PROVISIONS
7.1 Funding Principles
The Parties receive funding according to the agreement with their NFO. Each party shall individually bear any
additional costs not covered by the received funding necessary to perform their tasks in accordance with the
Consortium Plan.
7.2 Justifying Costs
In accordance with its own usual accounting and management principles and practices, each Party shall be solely
responsible for justifying its costs with respect to the Project towards the respective NFO. Neither the
Coordinator nor any of the other Parties shall be in any way liable or responsible for such justification of costs
towards the respective NFO.
7.3 Financial Consequences of the termination of the participation of a Party
A Defaulting Party shall, within the limits specified in Section 5.2 of this Consortium Agreement, bear any
reasonable and justifiable additional costs occurring to the other Parties in order to perform its and their tasks.
12 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
8 RESULTS
8.1 Ownership of Results
Results are owned by the Party that generates them.
If the researchers of a Party are entitled to claim rights to the Results pursuant to national laws or the funding
terms of the NFO in question, the Party concerned must ensure that these researchers comply with the
obligations under this Consortium Agreement.
If a third party generates Results, the Party concerned must obtain all necessary rights (transfer, licences or other)
from the third party, in order to be able to respect its obligations as if those Results were generated by the Party
itself. If obtaining the rights is impossible, the Party must refrain from using the third party to generate the
Results.
8.2 Joint Ownership
Two or more beneficiaries own Results jointly if:
(a) they have jointly generated them and
(b) it is not possible to separate them for the purpose of applying for, obtaining or maintaining their protection.
Where the Joint Results would be generated in part by the staff of a joint research unit (such as an "UMR" Unité
Mixte de Recherche.), the establishments managing said unit shall be considered as a single co-owner. It is
understood that these establishments shall be personally responsible for the allocation of the co-ownership
share allocated to them, pursuant to the agreements in place between them.
The joint owners must agree (in writing) on the allocation and terms of exercise of their joint ownership (“Joint
Ownership Agreement”), to ensure compliance with their obligations under this Consortium Agreement.
Such agreement shall be drawn up as soon as necessary and in any event before any industrial and/or commercial
exploitation of the jointly owned Results.
This Joint Ownership Agreement shall cover in particular:
- How the ownership is divided between the joint owners,
- How the jointly owned Results will be protected, including issues concerning the division of the related
cost of protection (e.g. patent filing and examination fees, renewal fees, prior state-of (the-art
searches, infringement actions, etc.),
- How the jointly owned Results will be exploited and disseminated and how the revenues or profits are
shared between the joint owners,
- The criteria for „fair and reasonable compensation“ to be provided to the non-exploiting joint owners,
- How disputes will be settled (e.g. via a mediator, applicable law, etc.).
The joint owners agree to endeavor the appointment among them of one joint owner in charge of the
management of the jointly owned Results.
Unless otherwise agreed in the Joint Ownership Agreement,
- each of the joint owners shall be entitled to use their jointly owned Results for non-commercial
research activities (which, for the avoidance of doubt, do not include research sponsored by a
commercial entity but include own internal non-commercial research and collaborative research with
or without public funding) on a royalty-free basis, and without requiring the prior consent of the other
joint owner(s), and
- each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant
non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are
given:
(a) at least 45 calendar days advance notice; and
(b) fair and reasonable compensation.
The joint owners shall agree on all protection measures and the division of related cost in advance.
13 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
Once the Results have been generated, joint owners may agree (in writing) to apply another regime than joint
ownership (such as, for instance, transfer to a single owner) but they must ensure that access rights
granted under this agreement are respected.
8.3 Protection of Results
The possible obligation of a Party to protect any Results is determined by the funding terms of the NFO in
question.
8.4 Transfer of Results
Each Party may transfer ownership of its own Results observing the limitations set forth herein.
A Party that intends to transfer ownership of Results must give at least 45 days prior notice (or less if unanimously
agreed in writing) to the other Parties.
The Parties recognize that in the framework of a merger or an acquisition of an important part of its assets, it
may be impossible under applicable EU and national laws on mergers and acquisitions for a Party to give the full
45 calendar days prior notice for the transfer.
Each party may identify specific third parties it intends to transfer the ownership of its Results to in Attachment
3 to this Consortium Agreement. The other Parties hereby waive their right to prior notice and their right to
object to a transfer to listed third parties.
The transferring Party shall, however, at the time of the transfer, inform the other Parties of such transfer and
shall ensure that the rights of the other Parties will not be affected by such transfer.
Any addition to Attachment 3 after signature of this Agreement requires a decision of the General Assembly.
The obligations above apply only for as long as other Parties still have - or still may request - Access Rights to the
Results.
8.5 Dissemination
For the avoidance of doubt, nothing in this Section 8.5 has impact on the confidentiality obligations set out in
Section 10.
8.5.1 Dissemination of own Results
During the Project and for a period of 1 year after the end of the Project, the Dissemination of own Results by
one or several Parties including but not restricted to publications and presentations, shall be subject to the
following provisions.
Prior notice of any planned publication shall be given to the other Parties at least 45 calendar days before the
submission of the publication. Any objection to the planned publication shall be made in accordance with this
Consortium Agreement in writing to the Coordinator and to the Party or Parties proposing the dissemination
within 30 calendar days after receipt of the notice. If no objection is made within the time limit stated above, the
publication is permitted.
An objection is justified if
- the protection of the objecting Party's Results or Background would be adversely affected and/or
- the objecting Party's legitimate academic or commercial interests in relation to the Results or
Background would be significantly harmed.
The objection has to include a precise request for necessary modifications.
If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the
objection on a timely basis (for example by amendment to the planned publication and/or by protecting
information before publication) and the objecting Party shall not unreasonably continue the opposition if
appropriate measures are taken following the discussion.
14 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
The objecting Party can request a publication delay of not more than 90 calendar days from the time it raises
such an objection. After 90 calendar days the publication is permitted, provided that Confidential Information of
the objecting Party has been removed from the Publication.
Possible open access obligations are determined by the funding terms of the respective NFO.
Authorship on publications shall be based on academic standards and custom. In accordance with normal
academic practice, all investigators and contributors to a publication will be acknowledged, always in compliance
with recognized standards concerning publication and authorship.
8.5.2 Dissemination of another Party’s unpublished Results or Background
A Party shall not include in any dissemination activity another Party's Results or Background without obtaining
the owning Party's prior written approval, unless they are already published.
8.5.3 Dissemination by NFO’s
Certain NFOs that are providing funding to Parties for their performance of their tasks under the Project, require
having the unlimited and unrestrictive right to publish the own Results of the Party that receives funding
therefrom. Consequently, notwithstanding anything contained to the contrary in this Agreement, such NFO’s
shall be permitted to publish at their own discretion and without any limitations, the own Results of the Party
that receives funding therefrom (including without limitation also own Results jointly owned with another Party
to the Project). Before any dissemination of jointly owned Results, the NFO has to obtain permission from all
joint owners.
8.5.4 Cooperation obligations
The Parties undertake to cooperate to allow the timely submission, examination, publication and defence of any
dissertation or thesis for a degree which includes their Results or Background subject to the confidentiality and
publication provisions agreed in this Consortium Agreement.
8.5.5 Use of names, logos or trademarks
Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or
otherwise the name of the Parties or any of their logos or trademarks without their prior written approval.
Display of the EJP-RD logo and the logo of the relevant NFO(s) shall be included in any project-specific
promotional material, press releases, reports, presentations and external websites, following the respective logo
guidelines of each organization.
9 ACCESS RIGHTS
9.1 Background included
In Attachment 1, the Parties have identified and agreed on the Background for the Project and have also, where
relevant, informed each other that Access to specific Background is subject to legal restrictions or limits. For the
avoidance of doubt, all Background used in connection with the Project shall remain the property of the Party
introducing the Background.
Anything not identified in Attachment 1 shall not be the object of Access Right obligations regarding Background.
Any Party may add further own Background to Attachment 1 during the Project by written notice to the other
Parties. However, approval of the General Assembly is needed should a Party wish to modify or withdraw its
Background in Attachment 1.
9.2 General Principles
Each Party shall implement its tasks in accordance with the Consortium Plan and shall bear sole responsibility for
ensuring that its acts within the Project do not knowingly infringe third party property rights.
Any Access Rights granted expressly exclude any rights to sublicense unless expressly stated otherwise.
15 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
Access Rights shall be free of any administrative transfer costs.
Access Rights are granted on a non-exclusive basis.
Results and Background shall be used only for the purposes for which Access Rights to it have been granted.
All requests for Access Rights shall be made in writing. The granting of Access Rights may be made conditional
on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended
purpose and that appropriate confidentiality obligations are in place.
The requesting Party must show that the Access Rights are Needed.
A request for Access Rights may be made up to twelve months after the end of the Project or, in the case of
Section 9.7.2, after the termination of the requesting Party’s participation in the Project.
Waivers of access rights are not valid unless in writing.
9.3 Access Rights for implementation
Access Rights to Results and Background Needed for the performance of the own work of a Party under the
Project shall be granted on a royalty-free basis, unless otherwise agreed for Background in Attachment 1.
9.4 Access Rights out of the Project
9.4.1 Access Rights to Results
Access Rights to Results if Needed for Exploitation of a Party's own Results shall be granted on Fair and
Reasonable conditions.
Access rights to Results for internal research activities shall be granted on a royalty-free basis.
9.4.2 Access Rights to Background
Access Rights to Background if Needed for Exploitation of a Party's own Results, including for research on behalf
of a third party, shall be granted on Fair and Reasonable conditions.
9.5 Access Rights for Affiliated Entities
Affiliated Entities have Access Rights under the conditions of this Consortium Agreement.
Access Rights must be requested by the Affiliated Entity from the Party that holds the Background or Results.
Alternatively, the Party granting the Access Rights may individually agree with the Party requesting the Access
Rights to have the Access Rights include the right to sublicense to the latter's Affiliated Entities if they are listed
in Attachment 4. Access Rights to Affiliated Entities shall be granted on Fair and Reasonable conditions and upon
written bilateral agreement.
Affiliated Entities which obtain Access Rights in return fulfil all confidentiality and other obligations accepted by
the Parties under this Consortium Agreement as if such Affiliated Entities were Parties.
Access Rights may be refused to Affiliated Entities if such granting is contrary to the legitimate interests of the
Party which owns the Background or the Results.
Access Rights granted to any Affiliated Entity are subject to the continuation of the Access Rights of the Party to
which it is affiliated, and shall automatically terminate upon termination of the Access Rights granted to such
Party.
Upon cessation of the status as an Affiliated Entity, any Access Rights granted to such former Affiliated Entity
shall lapse.
Further arrangements with Affiliated Entities may be negotiated in separate agreements.
16 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
9.6 Additional Access Rights
For the avoidance of doubt, any grant of Access Rights not covered by this Consortium Agreement shall be at the
absolute discretion of the owning Party and subject to such terms and conditions as may be agreed between the
owning and receiving Parties.
9.7 Access Rights for Parties entering or leaving the consortium
9.7.1 New Parties entering the consortium
As regards Results developed before the accession of the new Party, the new Party will be granted Access Rights
on the conditions applying for Access Rights to Background.
9.7.2 Parties leaving the consortium
9.7.2.1 Access Rights granted to a Defaulting Party
Access Rights granted to a Defaulting Party and such Party's right to request Access Rights shall cease
immediately upon receipt by the Defaulting Party of the formal notice of the decision of the General Assembly
to terminate its participation in the consortium.
9.7.2.2 Access Rights granted to a non-defaulting Party:
A non-defaulting Party leaving voluntarily and with the other Parties' consent shall have Access Rights to the
Results developed until the date of the termination of its participation.
It may request Access Rights within the period of time specified in Section 9.2.
9.7.2.3 Access Rights to be granted by any leaving Party
Any Party leaving the Project shall continue to grant Access Rights pursuant to this Consortium Agreement as if
it had remained a Party for the whole duration of the Project.
9.8 Specific Provisions for Access Rights to Software
For the avoidance of doubt, the general provisions for Access Rights provided for in this Section 9 are applicable
also to Software.
Parties’ Access Rights to Software do not include any right to receive source code or object code ported to a
certain hardware platform or any right to receive respective Software documentation in any particular form or
detail, but only as available from the Party granting the Access Rights.
10 NON-DISCLOSURE OF INFORMATION
10.1 Confidential Information
All information in whatever form or mode of communication, which is disclosed by a Party (the “Disclosing
Party”) to any other Party (the “Recipient”) in connection with the Project during its implementation and which
has been explicitly marked as “confidential” at the time of disclosure, or when disclosed orally has been identified
as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar
days from oral disclosure at the latest as confidential information by the Disclosing Party, is “Confidential
Information”.
10.2 Obligations of the Recipient
The Recipients hereby undertake, for a period of 4 years after the end of the Project
- not to use Confidential Information otherwise than for the purpose for which it was disclosed;
- not to disclose Confidential Information without the prior written consent by the Disclosing Party;
- to ensure that internal distribution of Confidential Information by a Recipient shall take place on a
strict need-to-know basis; and
- to return to the Disclosing Party, or destroy, on request all Confidential Information that has been
disclosed to the Recipients including all copies thereof and to delete all information stored in a
17 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
machine readable form to the extent practically possible. The Recipients may keep a copy to the extent
it is required to keep, archive or store such Confidential Information because of compliance with
applicable laws and regulations or for the proof of on-going obligations provided that the Recipient
comply with the confidentiality obligations herein contained with respect to such copy for as long as
the copy is retained.
The recipients shall be responsible for the fulfilment of the above obligations on the part of their employees or
third parties involved in the Project and shall ensure that they remain so obliged, as far as legally possible, during
and after the end of the Project and/or after the termination of the contractual relationship with the employee
or third party.
The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within
the scope of the Project as with its own confidential and/or proprietary information, but in no case less than
reasonable care
10.3 Exceptions to Confidentiality obligations
The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can
show that:
- the Confidential Information has become or becomes publicly available by means other than a breach
of the Recipient’s confidentiality obligations;
- the Disclosing Party subsequently informs the Recipient that the Confidential Information is no longer
confidential;
- the Confidential Information is communicated to the Recipient without any obligation of
confidentiality by a third party who is to the best knowledge of the Recipient in lawful possession
thereof and under no obligation of confidentiality to the Disclosing Party;
- the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant
Agreement;
- the Confidential Information, at any time, was developed by the Recipient completely independently
of any such disclosure by the Disclosing Party;
- the Confidential Information was already known to the Recipient prior to disclosure, or
- the Recipient is required to disclose the Confidential Information in order to comply with applicable
laws or regulations or with a court or administrative order, subject to the provision Section 10.7
hereunder.
10.4 Duty to Notify
Each Party shall promptly advise the other Party in writing of any unauthorised disclosure, misappropriation or
misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or
misuse.
If any Party becomes aware that it will be required, or is likely to be required, to disclose Confidential Information
in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the
extent it is lawfully able to do so, prior to any such disclosure
- notify the Disclosing Party, and
- comply with the Disclosing Party’s reasonable instructions to protect the confidentiality of the
information.
11 MISCELLANEOUS
11.1 Attachments, inconsistencies and severability
This Consortium Agreement consists of this core text and
- Attachment 1 (Background included)
- Attachment 2 (Accession document)
- Attachment 3 (List of Third Parties for simplified transfer according to Section 8.4)
- Attachment 4 (Identified Affiliated Entities)
18 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
- Attachment 5 (Form for transfer of biological materials
- Attachment 6 : HUS MTA agreement with 3 annexes)
- Attachment 7 (Commitment to EJP RD ethical requirements)
In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall
prevail.
Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect
the validity of the remaining provisions of this Consortium Agreement. In such a case, the Parties concerned shall
be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original
provision.
11.2 No representation, partnership or agency
No Party shall be entitled to act or to make legally binding declarations on behalf of any other Party or of the
consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency,
partnership, interest grouping or any other kind of formal business grouping or entity between the Parties.
11.3 Notices and other communication
Any notice to be given under this Consortium Agreement shall be in writing to the addresses and recipients as
listed in the most current address list kept by the Coordinator.
Formal notices:
If it is required in this Consortium Agreement (Sections 4.3, 9.7.2.1, and 11.4) that a formal notice, consent or
approval shall be given, such notice shall be signed by an authorized representative of a Party and shall either be
served personally or sent by mail with recorded delivery.
Other communication:
Other communication between the Parties may also be effected by other means such as e-mail with
acknowledgement of receipt, which fulfils the conditions of written form.
Any change of persons or contact details shall be notified immediately by the respective Party to the Coordinator.
The address list shall be accessible to all concerned.
11.4 Assignment and amendments
Except as set out in Section 8.2, no rights or obligations of the Parties arising from this Consortium Agreement
may be assigned or transferred, in whole or in part, to any third party without the other Parties’ prior formal
approval.
Amendments and modifications to the text of this Consortium Agreement not explicitly listed in Section 6.2.7
require a separate written agreement to be signed between all Parties.
11.5 Mandatory national law
Nothing in this Consortium Agreement shall be deemed to require a Party to breach any mandatory statutory
law under which the Party is operating.
11.6 Language
This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings,
arbitral proceedings and processes relative thereto.
11.7 Applicable law
This Consortium Agreement shall be construed in accordance with and governed by the laws of Belgium excluding
its conflict of law provisions.
19 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
11.8 Settlement of disputes
The parties shall endeavour to settle their disputes amicably.
If, however, no settlement of any dispute under this Consortium Agreement has been possible to achieve, after
the Parties’ reasonable endeavours to settle such dispute(s) amicably, the Parties agree to submit the matter to
settlement proceedings under the International Chamber of Commerce Alternative Dispute Resolution (ADR)
Rules.
If, and to the extent that, any such dispute, controversy or claim has not been settled pursuant to the mediation
within 60 calendar days following the filing of a request for ADR pursuant to the said Rules, the courts of Brussels
shall have exclusive jurisdiction.
Nothing in this Consortium Agreement shall limit the Parties' right to seek injunctive relief in any applicable
competent court
12 SIGNATURES
AS WITNESS:
The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised
representatives.
UNIVERSITY OF HELSINKI (“UH”)
Henna Tyynismaa
Director of Research Programs Unit, University of Helsinki
HOSPITAL DISTRICT of HELSINKI AND UUSIMAA (“HUS”)
Anne Pitkäranta
Research Director
Université de Nantes (UN)
For the legal representative, per delegation
Sébastien YOUINOU
Director of research, partnerships and innovation
20 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
University of Tartu (“UT”)
Taivo Raud
Head of Grant Office
INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES
Maria M. Mota
Executive Director
21 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
ATTACHMENT 1: BACKGROUND INCLUDED
According to the Consortium Agreement Background is defined as “data, know-how or information (…) that is needed
to implement the action or exploit the results”. Because of this need, Access Rights have to be granted in principle,
but Parties must identify and agree amongst them on the Background for the project. This is the purpose of this
attachment.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 1: UNIVERSITY OF HELSINKI
As to the University of Helsinki, it is agreed between the Parties that, to the best of their knowledge,
no data, know-how or information of University of Helsinki shall be Needed by another Party for implementation of
the Project or Exploitation of that other Party’s Results.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 2 HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA
As to the Hospital District of Helsinki and Uusimaa, it is agreed between the Parties that, to the best of their
knowledge,
No data, know-how or information of Hospital District of Helsinki and Uusimaa shall be Needed by another Party for
implementation of the Project or Exploitation of that other Party’s Results.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 2: UNIVERSITE DE NANTES
As to Université de Nantes, it is agreed between the Parties that, to the best of their knowledge, the following
background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as
mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
Thymics APCs rat model Complementary provisions to the Not available for Access Rights by
MTA clauses in the Agreement may the Parties for Exploitation
be added if necessary.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 3: UNIVERSITY OF TARTU
As to the University of Tartu, it is agreed between the Parties that, to the best of their knowledge,
no data, know-how or information of University of Tartu shall be Needed by another Party for implementation of the
Project or Exploitation of that other Party’s Results.
This represents the status at the time of signature of this Consortium Agreement.
PARTY 4: INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES
As to INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES, it is agreed between the Parties that, to the best
of their knowledge, the following background is hereby identified and agreed upon for the Project.
22 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
Describe Background Specific limitations and/or conditions Specific limitations and/or conditions
for implementation (Article 25.2 for Exploitation (Article 25.3 Grant
Grant Agreement) Agreement)
Identification of germinal centres none none
based on the phenotype of Tfh and
Tfr cells within the tissue
Transcriptional signatures of Tfh, Tfr none none
and regulatory T cells (Treg) cells
from tissues with GCs
(tonsil) and without GCs (LN and
blood).
This represents the status at the time of signature of this Consortium Agreement.
23 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
ATTACHMENT 2: ACCESSION DOCUMENT
ACCESSION of a new Party to
[Acronym of the Project] Consortium Agreement, version […, YYYY-MM-DD]
[OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE Grant Agreement]
hereby consents to become a Party to the Consortium Agreement identified above and accepts all the rights and
obligations of a Party starting [date].
[OFFICIAL NAME OF THE COORDINATOR AS IDENTIFIED IN THE Grant Agreement]
hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new
Party] to the consortium starting [date].
This Accession document has been done in 2 originals to be duly signed by the undersigned authorised
representatives.
[Date and Place]
[INSERT NAME OF THE NEW PARTY]
Signature(s)
Name(s)
Title(s)
[Date and Place]
[INSERT NAME OF THE COORDINATOR]
Signature(s)
Name(s)
Title(s)
24 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
ATTACHMENT 3:
LIST OF THIRD PARTIES FOR SIMPLIFIED TRANSFER ACCORDING TO SECTION 8.4.
For Nantes Université: SATT OUEST VALORISATION (TTO)
ATTACHMENT 4: IDENTIFIED AFFILIATED ENTITIES ACCORDING TO SECTION 9.5
NONE
25 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
ATTACHMENT 5: FORM FOR TRANSFER OF BIOLOGICAL MATERIALS AND / OR DATA
The Supplier (as defined below) agrees to the transfer of or access to the Material and/or Data (described below) to
the Recipient (as defined below) for the conduct of the Project in accordance with the terms and conditions of the
Consortium Agreement TARID No. ……………..
Materials Designation:
…………………………………………………………………….
Quantities:
…………………………………………………………………….
Data Designation:
…………………………………………………………………….
Form:
…………………………………………………………………….
Party supplying or giving access to the …………………………………………………………………….
Material and/or Data
(the “Supplier”)
Name and address of the laboratory supplying …………………………………………………………………….
or giving access to the Material and/or Data
Contact details of the scientist supplying or Name: ……………………………………………………………..
giving access to the Material and/or Data
Email: …………………………………………………………….
Tel: ………………………………………………………………..
Fax: ……………………………………………………………….
Recipient party for the Material and/or Data ………………………………….………………………………….
(the “Recipient”)
Delivery address for the Material and/or Data Address …………………………………………………………..
……………………………………………………………………..
Name of recipient ……………………………………………….
Email: …………………………………………………….……….
Tel: ……………………………………………………….………..
Fax: ……………………………………………………….……….
Signed in [-](-) original counterparts drafted in the English language, with one (1) for the Supplier and the other(s) for
the Recipient
Witnessed, the Scientific Manager of Supplier Witnessed, the Scientific Manager of Recipient
26 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
ATTACHMENT 5: TEMPLATE FOR MATERIAL TRANSFER AGREEMENT FOR MATERIALS OWNED BY HUS INCLUDING
ATTACHMENTS A, B, C
MATERIAL TRANSFER AGREEMENT
1. PARTIES
This agreement on the transfer of biological materials ("agreement") is signed between the sample
principal, responsible for sample:
Hospital District of Helsinki and Uusimaa (hereinafter referred to as ”HUS”)
Stenbäckinkatu 9, P.O.Box 100, FI-00029 Helsinki, Finland
Business ID 1567535-0
and
University, Institution or Company (hereinafter referred to as ”recipient”)
Registered address
Business ID
hereafter together referred to as “parties”.
Recipient cannot assign or sublicense its rights or obligations under this agreement to any third party
without the prior written permission of HUS.
WHEREAS
Parties are already engaged in collaborative research in the frame of the European Joint Programme on
Rare Diseases (“EJP RD”).
The present MTA takes place in the contexte the TARID (Thymic Abnormalities in Rare Immunological
Diseases) project.
Parties are already bound by the TARID Consortium Agreement (2020_00105), together with third Parties.
2. TRANSFER OF BIOLOGICAL MATERIALS AND DATA
HUS is in possession of a certain biological materials, samples and associated personal data (“Material”),
which need to be analyzed within the framework of the research project of the recipient. HUS collaborates
with the principal investigator for the specific research project (see paragraph 4).
The parties wish the recipient to be able to analyze the Material(s) in a research project and the HUS agrees
to make the mentioned Material available to the recipient for the specific research project purposes.
HUS undertakes to assist the recipient with the transfer of the Material(s) specified in attachment 1, for
specific analyses/research. Material(s) for analysis/research is provided in pseudonymized form, i.e. coded
samples and coded personal data so that an individual donor cannot be identified.
HUS undertakes to keep a code key for the identification of samples/Material during the term of this
agreement. The recipient acknowledges that HUS cannot send any information about the sample/ Material(s)
that can identify the sample donor to recipient. Personal data under this agreement means any information
that is directly or indirectly attributable to a natural person. All rights and title to the transferred Material(s)
remain with the HUS.
Recipient shall cover any reasonable work, shipping and related costs, unless otherwise agreed.
The fee for the said costs is [approximately] in the amount of: [Insert the possible fee].
27 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
3. PERMITTED USE
Recipient declares that research project has been approved by an ethics committee/IRB.
HUS makes no representations that the use does not infringe any rights of third parties and makes no
representation and gives no warranty or undertaking, in relation to the Material(s). As examples, but without
limiting the foregoing, HUS gives no warranty: i) that it owns all necessary property and other rights in the
Material(s) and that their use will not infringe any patent, copyright, trade mark or other right owned by any
third party; or ii) that the Material(s) are of merchantable or satisfactory quality or fit for any particular
purpose, have been developed with reasonable care and skill or tested for the presence of pathogens or
otherwise, or are viable, safe or non-toxic.
The recipient acknowledges that the Material(s) is made available for experimental use only and should not
be used in humans.
The recipient agrees to use the submitted Material(s), solely as described in attachment 2, in accordance
with applicable laws, regulations, policies, guidelines, ethical standards and under all circumstances solely
according to the patient’s consent.
4. ACCESS TO THE MATERIALS
The recipient agrees to ensure that only those persons involved in the research project and principal
investigator have access to and the use of the Material(s) for the research.
The recipient shall take all reasonable measures to secure the safety and confidentiality of the Material(s),
any derivatives and data and for that purpose, but without limitation, shall ensure that all research personnel
are similarly bound by appropriate undertakings contained in the contracts under which such research
personnel are employed or render services to the recipient, or otherwise as appropriate in the circumstances.
(“PI of the recipient”): [Insert the name, department and address of the scientist receiving the material]
5. SECURITY FOR MATERIALS
The recipient ensures that Material(s) is protected from unauthorized use and of theft.
The recipient agrees to abide by and meet the requirements and instructions from HUS in attachment 3.
The recipient acknowledges that it under no circumstances shall use the Material(s) transferred under this
agreement to identify individuals or to contact any individual whose biological material it has dealt with. If
the recipient becomes aware of any unauthorized use or disclosure of the use of Material(s), the recipient
undertakes to contact HUS without delay.
6. RESULTS AND PUBLICATIONS
Parties will apply section 8 of the TARID Consortium Agreement.
7. INDEMNITY
HUS is not responsible for the recipient´s use of Material(s) and in case of loss, damage or liability which may
arise from or in connection with this agreement or the equivalent in case of storage or transport of
Material(s) to the recipient.
28 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
Subject to section 5 of the TARID Consortium Agreement, the recipient agrees to indemnify and hold
harmless HUS and its employees, whether in contract, delict or otherwise, against any loss, claim, and
damage caused as a result of the use, keeping, storage or transport of the Material(s) or the consequences
of its use under this agreement – including but not limited to i) injury to the recipient and/or its employees
and third parties; ii) infringement of third party intellectual property rights and iii) use of the Materials within
or outside the scope of this agreement.
The recipient is liable to HUS for any damage caused to HUS or the patients by third parties it has transferred
to or disclosed the Material(s).
8. TERM AND TERMINATION OF THIS AGREEMENT
This agreement shall enter into force on [date] and shall remain in force for two (2) years or until research
under the research plan has been completed, whichever occurs first.
This agreement may be terminated by either party for any reason, by giving the other party thirty (30) day´s
written notice.
HUS has the right to terminate this agreement with immediate effect if the recipient is in breach of its
obligations under this agreement or is bankrupt or under liquidation.
All confidentiality and other obligations of a continuing nature contained herein shall remain in force and
shall survive this agreement notwithstanding its termination as aforesaid.
9. TERMINATION OF TREATMENT OF MATERIALS AND DATA
The recipient agrees on expiry of this agreement to stop the use of the Material(s).
Unless otherwise agreed between the Parties, the recipient also agrees to return or destroy the Material(s)
and any copies of coded personal data obtained by recipient as instructed by HUS, when the research
according to the research plan is complete, or within thirty (30) days after termination or expiration of this
agreement, whichever occurs first.
The principal investigator and the recipient are responsible for the destruction or return of the Material(s).
The recipient shall however have the right to retain such copies as are required to comply with applicable
laws, rules and regulations.
10. OTHER
No provision of this agreement may be amended or modified, except by written instrument duly executed
by the parties.
All communications concerning this agreement shall be in writing and shall be delivered to the address
indicated below, unless party has specifically been notified by the other party of another address for this
purpose.
Message is delivered in person, by mail, e-mail or fax. A receipt shall always be provided for each received
message.
11. APPLICABLE LAW AND DISPUTES
29 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
This Agreement shall be governed by and construed in accordance with the laws of Finland or with the laws
of the jurisdiction of the origin of the sample without regard to its conflict of laws rules.
Any dispute, controversy or claim arising out of or in connection with this Agreement shall be resolved
amicably. In case an amicable resolution is not agreed upon within 30 days, a Party may take the dispute to
be finally settled by the District Court of Helsinki or by the local Court of the jurisdiction of the origin of the
sample.
This agreement is executed in two (2) originals, where both parties have taken one (1) each.
HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA
____/___.2019
_________________________ _____________________
Anne Pitkäranta, [insert name],
Research Director toimialan tutkimuksen ja opetuksen vastuuhenkilö
RECIPIENT:
____/____.2019
__________________________ ______________________________
30 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
ATTACHMENT 1 TO HUS MTA: BIOLOGICAL MATERIAL
Description of biological material and personal data to be transferred.
Pseudonymized and patient unidentifiable to recipient xxx [insert sample type],
samples from [patient type with diagnosis] in the amount of [number of samples, type of samples for
instance plasma, serum, urine etc. each identified in number] ---
previously collected by HUS for [insert study/research/purpose for collecting and to what end they were
collected]. Minor changes in the amounts indicated above may occur.
ATTACHMENT 2 TO HUS MTA: RESEARCH TO BE CONDUCTED
Research Plan:
Detailed specification of the purposes for which biological material and personal data may be used:
HUS’s materials, will be used for assessment of
[insert the following:
- the purpose and study or research for which the samples shall be used
- what organization and to which department/unit etc].
All samples are identified by a numerical code; patient-identifiable data are not available to
recipient.
31 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
ATTACHMENT 3 TO HUS MTA: INFORMATION SECURITY ANNEX
1. Purpose and application of this document
This document is an annex to the Agreement concluded between the Parties to the TARID consortium Agreement
(hereafter “the Contracting Parties”) by which matters related to the data protection, information security and
processing and secrecy of a Contracting Party’s material of the subject of the Agreement are agreed upon. This
document shall be applied in accordance with the order of precedence of contract documents stated in the Agreement,
with due regard to what is stated below on the application of potential limitations of liability under the Agreement.
2. Definitions
Personal data: means any information relating to an identified or identifiable natural person (‘data subject’); an
identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier
such as a name, an identification number, location data, an online identifier or to one or more factors specific to the
physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.Defined in Article 4
of the Data Protection Regulation.
Processing of personal data: Defined in Article 4 of the Data Protection Regulation Processing of personal data refers,
for example, to the Processor's opportunity to view personal data in connection with the implementation of the subject
of the Agreement.
Data Protection Regulation or GDPR: Regulation (EU) 2016/679 of the European Parliament and of the Council on the
protection of natural persons with regard to the processing of personal data and on the free movement of such data,
and repealing Directive 95/46/EC.
Material: documents, written information, databases and software to be used in connection with the supply of the
product or in connection with the service, and other material that a Party has submitted to the Processor for the purpose
of providing a product or a service, including data material that is created when the service or product is used, its design,
structure and metadata. The structure of the data material does not refer to its structure in terms of storage technology
but to its conceptual design and parsing for the purposes of use. Storage technically, the data material can be contained
in files, databases or other storage formats. In this definition, data content and data refer to both raw data and
processed data.
3. General obligations
a. Contracting Parties’ obligation to comply with legislation
The Contracting Parties undertake to comply with the legislation on information security, data protection, publicity and
confidentiality and the official regulations issued thereunder. The Agreement shall not derogate from the mandatory
obligations imposed on a Contracting Party by law.
b. Obligation to co-operate
The Contracting Parties shall use all reasonable endeavours to contribute to the attainment of a high level of information
security in the implementation of the subject of the Agreement and to the other Contracting Party’s opportunity to
maintain it on its own part.
c. Due care obligation
The Contracting Parties shall ensure that the duties foreseen hereunder are carried out with due care and that the
confidentiality, availability or integrity of CONTROLLER’s material or confidential information is not endangered as a
result of negligence, incorrect working methods or other conduct at variance with the Agreement.
d. Duties and responsibilities related to information security
The Contracting Parties shall define the duties and responsibilities related to information security in their respective
organisations, assign persons in charge with sufficient experience and competence, and communicate their contact
details to the other Contracting Party.
e. In-house instructions related to information security
32 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
The Contracting Parties may have separate in-house instructions related to information security. The Contracting Parties
shall comply with them insofar as they are not in conflict with the Agreement. The Contracting Parties shall take the
other Party’s in-house instructions related to information security into account as far as possible.
4. CONTROLLER's material
a. Handling
In the handling of CONTROLLER’s material, the Processor shall comply with the good practice on information
management in accordance with the legislation applicable in medical research, the good data processing practice
required under data protection legislation, other legislation concerning the protection of data and privacy protection,
other applicable legislation mentioned in the Agreement as well as reasonable instructions given by CONTROLLER. If the
Processor prepares or processes patient documents under the Agreement, the Processor commits to preparing and
processing the said documents in accordance with the specific the rules for preparing and processing patient documents
and the instructions given by CONTROLLER as the controller.
b. Intended use
The Processor may only use CONTROLLER’s material for the implementation of the subject of the Agreement and only
to the extent that is necessary for the implementation of the subject of the Agreement. The Processor shall see to it
that the CONTROLLER’s material is only processed by authorised research personnel working for and on behalf of the
Processor whose work duties involve the processing CONTROLLER’s material.
c. Information security levels
CONTROLLER shall have the right to define different information security levels and related special information security
measures and instructions for CONTROLLER’s material. The Processor shall process CONTROLLER's material in
accordance with the requirements for its information security level. In the event that changes to the information
security levels give rise a substantial amount of additional work for the Processor, the Contracting Parties shall address
the matter in accordance with the change management procedure.
d. Information requests
The Processor shall forward any third-party information requests concerning CONTROLLER’s material immediately to
CONTROLLER.
e. Returning CONTROLLER’s material
Upon expiry of the Agreement or when the need to use the material no longer exists, the Processor shall return
CONTROLLER’s up-to-date material to CONTROLLER within 14 days of CONTROLLER’s written request to this effect in
accordance with the data material openness requirement, unless otherwise agreed upon in the Agreement. The data
material openness requirement means that the data material of CONTROLLER is available in a generally used format
and accessible with generally used information systems without any royalties or licence fees or other conditions limiting
its use. The Processor is not entitled to any separate compensation for the delivery of CONTROLLER's material in
accordance with this subparagraph 5.5.
f. Destroying CONTROLLER’s material
The Processor shall, at its own cost, destroy any copies of CONTROLLER's material in a data secure manner when
CONTROLLER has confirmed, in writing, that CONTROLLER’s material had been returned in accordance with the
Agreement. The Processor shall, at CONTROLLER’s request, present reasonable evidence of destroying the material
without any separate compensation. The Processor is not liable to destroy the material if the Processor is obligated to
retain the material concerned under law or official regulation.
5. Processing of personal data
This paragraph 6 shall apply in the event that the Processor processes personal data under the Agreement. Also the
conditions concerning CONTROLLER's material, among others, shall be applied to the processing of personal data.
a. Processor’s right to process personal data
CONTROLLER is within the meaning of data protection legislation and the Processor, a processor of personal data.
33 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
The Processor shall have the right to process the personal data contained in CONTROLLER’s material
only on the grounds indicated in the Agreement or with CONTROLLER’s prior written permission;
only to the extent and as long as it is necessary for the implementation of the subject of the Agreement;
only in accordance with the data subjects’ consent and/or valid permits, as indicated in the Agreement;
only in accordance with this Agreement and the documented instructions separately given by CONTROLLER.
The following matters are addressed in greater detail in the Project, other annexes hereto or other documentation
related to the Agreement:
the subject and duration of the processing of personal data;
the nature and purpose of the processing of personal data;
the type of the personal data;
the categories of data subjects;
the controller’s obligations and rights (insofar as they have not been indicated in this Annex).
b. Complying with data protection legislation
In the processing of personal data, the Processor undertakes to comply with the current data protection legislation and
the official regulations issued thereunder. The Processor warrants that it is familiar with the content of the Data
Protection Regulation, for example, including, but not limited to, the obligations imposed on a processor in Articles 28
and 32. Any conduct of the Processor that is contrary to the data protection legislation may be considered a material
breach of contract.
The Processor shall immediately notify CONTROLLER if it suspects that the Agreement or the instructions or any practice
used in the implementation of the subject of the Agreement are at variance with data protection legislation.
c. Actions to secure compliance with the requirements of data protection legislation
The Processor is required to assess the risks associated with processing of personal data in view of the data subjects
and to implement appropriate technical and organisational measures to ensure that the processing of personal data
meets the requirements of data protection legislation and to safeguard the protection of the rights of the data subject.
The technical and organisational measures must be recorded in writing and the documentation must be kept up-to-
date. Among other things, the Processor shall see to the proper protection of the personal data it processes to ensure
their confidentiality, integrity and availability, and abide by the principle of data protection by design and by default in
the implementation of the subject of the Agreement.
The Processor shall designate a data protection officer pursuant to Article 37 of the Data Protection Regulation and
communicate their contact details on their public website or directly to CONTROLLER.
d. Use of other processors of personal data
The Processor may not retain the services of other processors of personal data without CONTROLLER’s prior written
permission. The Processor shall notify CONTROLLER in advance in writing of any planning changes concerning the adding
or replacement of other processors of personal data, in which case CONTROLLER may, for a well-founded reason, deny
the change. The Processor is responsible for ensuring that a proper contract that meets the obligations posed by data
protection legislation has been concluded between the Processor and the other processor of personal data.
e. Processor’s obligation to assist and provide information
The Processor shall assist CONTROLLER in fulfilling its obligation to respond to requests that concern the exercise of the
data subject's rights pursuant to data protection legislation and in ensuring that the obligations set forth in Articles 32
through 36 of the Data Protection Regulation are complied with. Among other things, the Processor shall assist
CONTROLLER in making the notifications required under Articles 33 and 34 of the Data Protection Regulation to the
supervisory authority and the data subject within the time period specified in the Data Protection Regulation. The
Processor shall also, on request, cooperate with the supervisory authority as provided under Article 31 in the
performance of its tasks.
34 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
The Processor shall provide CONTROLLER with all the information that is necessary for proving compliance with the
obligations imposed by data protection legislation. The Processor shall constantly maintain the said information and
assess the adequacy of the actions.
The Processor shall, on its own initiative, communicate to CONTROLLER the places where the processing of personal
data takes place and any changes to them if they are not clearly stated in the Agreement or in the documentation
available to CONTROLLER.
The Processor shall fulfil its obligation to assist and provide information under this subparagraph 6.5 without any
separate compensation.
f. Processing of personal data abroad
The Processor may not process the personal data included in CONTROLLER’s material in any other way than stated in
the Agreement or in annexes that are ranked higher in the order of precendence than this annex, in respect of GDPR.
Unless otherwise expressly stated in the Agreement or in annexes that are ranked higher in the order of precedence
than this annex, the Processor may not process the personal data included in CONTROLLER’s material outside of the
European Economic Area (EEA).
If, according to the Agreement or an annex that is ranked higher in the order of precedence than this annex, the
Processor is allowed to process the personal data included in CONTROLLER’s material outside of the EEA, the Processor
shall notify CONTROLLER of the commencement of such processing of personal data in writing no later than 30 days
before the planned commencement date.
If the Processor processes personal data in any county other than those listed as trusted countries by the EU
Commission, the Processor undertakes to conclude a separate contract on the processing of personal data with
CONTROLLER in accordance with the EU model clauses before the processing of personal data is commenced. In the
event that an agreement based on the EU model clauses would not, at a later date, be considered as a sufficient means
of compliance with the requirements of data protection legislation, the Processor commits to regularising, without
delay, the processing of personal data together with CONTROLLER.
The Processor undertakes to transfer the processing of personal data to the EEA or to a trusted country without undue
delay if the processing country is removed from the list of trusted countries. CONTROLLER may not incur any additional
costs as a result of the transfer.
The Processor shall guarantee the same level of information security and data protection irrespective of the country
where the personal data are processed.
g. Damages
If the Processor has acted in contravention with the Data Protection Regulation as a result of which CONTROLLER or a
data subject has incurred material or immaterial loss or damage, the Processor shall be liable to compensate such loss
or damage.
If an administrative fine referred to in Article 83 of the Data Protection Regulation is imposed on CONTROLLER and the
fine is proven to be attributable to an act or omission of the Processor or its subcontractor or an individual in their
employ, the Processor shall be liable to compensate the euro amount of the administrative fine to CONTROLLER in full
irrespective of any limitation of liability potentially included in the Agreement.
6. Processor’s obligations to notify and report
a. Obligation to notify
The Processor shall, without undue delay, notify CONTROLLER of any circumstances that have come to the Processor’s
attention that may have an effect on the information security related to the subject of the Agreement and of the
measures and any consequences resulting from them. The obligation concerns, among other things, information
security risks, changes to security arrangements, actual or attempted information security violations, unpatched system
vulnerabilities, denial-of-service attacks and other similar nonconformances that are likely increase the risk posed to
the confidentiality, integrity and availability of CONTROLLER’s material. The Processor shall inform CONTROLLER of a
responsible person to provide further information. If the circumstance in question is related to personal data, the
Processor shall notify CONTROLLER of the related data subject groups and the estimated numbers.
35 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
b. Periodic reporting
The Processor shall monitor the attainment of the level of information security specified in the Agreement on a regular
basis and in a systematic manner. The Processor shall record any nonconformances and report them without delay and
initiate corrective actions as soon as possible.
7. Actions in the event of an information security breach
The Processor shall have in place written instructions on how to act in the event of information security breaches.
TheCONTROLLER shall be liable to assist Processor in minimising the damage related to data security breaches and in
clarifying the matter with the authorities.
8. Other terms and conditions
a. Preparation of descriptions and statements
CONTROLLER shall be responsible for the preparation of a personal data file description, privacy statement, description
of processing operations, impact assessment and information system description and for the implementation of prior
consultation. The Processor shall provide CONTROLLER with the information needed in preparing and implementing the
above without any separate compensation according to the GDPR.
b. Amendments to the Agreement due to reasons related to information security or data protection
and additional work
If recommendations, guidelines or regulations related to the legislation on information security or data protection or its
interpretation change, the Contracting Parties shall make the necessary amendments to the Agreement. has the right
to order a necessary amount of additional work from the Processor in order to implement the amendments to the
Agreement or to HUS's guidelines on the processing of personal data.
36 / 37
Restricted diffusion
2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020
37 / 37
Restricted diffusion
Tartu ülikooli eesmärgid TARID projektis 1.09.2020 – 30.08.2023
Vastutav täitja Pärt Peterson, PhD, molekulaarimmunoloogia professor, Bio- ja siirdemeditsiini
instituut, Tartu ülikool. Email:
[email protected]
TARID projekti laiem eesmärk on leida vastust - miks tekivad organismis autoimmuunsed reaktsioonid, kui
tüümuses ei toimi üks olulisemaid immuuntolerantsust reguleerivaid geene, Autoimmuunne Regulaator
(AIRE)? Kas neid vigu on võimalik ravilahendustega parandada?
AIRE geeni vea korral hakkab organismi immuunsüsteem ründama iseennast. Teisisõnu tekib
autoimmuunne reaktsioon. Põhjuseks on, et tüümusest ei eemaldata autoreaktiivseid T rakke; need
reageerivad inimese enda antigeenidega, hävitatavad organismi kudesid ning haiguse 1. tüüpi
autoimmuunne polüendokrinopaatia sündroom tagajärjel tekivad patsientidel mitmed autoimmuunsed
haigused, mille mehhanismid on ebaselged. Lisaks on AIRE geeni puudus seotud müasteeniaga, mis
seotud tümoomiga, tüümuse epiteeli kasvajaga.
Kuna mehhanistliku tausta selgitamine otse inimeses on praktiliselt võimatu, siis on AIRE geeni ja seotud
haiguste põhjuste selgitamiseks välja töötatud AIRE-puuduliku looma mudel rotis, kelles tekib inimesega
sarnane haigussündroom. Inimese haigust peegeldava katseloomamudeli olemasolu võimaldab
analüüsida immuunsüsteemi süvitsi, leida haiguse tagamaid ja loodetavasti testida ka võimalikke
ravilahendusi.
Tartu Ülikooli poolsed TARID projekti tegevused.
Esimene projekti aasta 1.09. 2020 – 31.08. 2021. Esimene aasta keskendub tüümuse ja põrna rakkude
eraldamisele ning transkriptoomilisele analüüsile AIRE-puudulikus ja terves rotimudelis. Et aru saada
autoimmmuunsest reaktsioonist ja märklaudadest mida immuunsüsteem ründab, leiame mis on
autoantigeenid antud loomades. Et mõista AIRE puuduliku geeni mõju tüümuses, loome tüümuse rakkude
puhastamise meetodi, eraldame koostöös teiste projekti partneritega AIRE-puudulikust rotist kui
katseloomast tüümuse rakud, määrame nende populatsioonide sagedused ja muutused. Seejärel teeme
ülegenoomi transkriptoomi analüüsi, et määrata geenide ekspressiooni mutused. Saadud tulemusi
võrdleme terve (ehk mitte geen-muudetud) katselooma geenide avaldumisega. Lisaks teeme üherakulise
transkriptoomi analüüsi katselooma tüümusele ning põrnale kui sekundaarsele immuunkoele, kus toimub
T rakkude aktivatsioon. Analüüsime saadud tulemusi bioinformaatiliselt.
Teine projekti aasta 1.09. 2021 – 31.08. 2022. Teine aasta keskendub T ja B rakulise immuunrepertuaari
määramisele AIRE-puudulikus ja terves rotimudelis. Et mõista autoimmuunset T ja B raku reaktsiooni,
uurime loodud katseloomades T ja B raku repertuaari. Imetajate immuunrepertuaarid on väga suured (kuni
1012 erinevat klooni). Selleks et sellise mastaapse kloonide kogumi muutustest aru saada, töötame esmalt
välja repertuaari analüüsi meetodi roti mudelile. Seejärel kui meetod toimib, eraldame rakud, neist RNA,
ning kasutades uue põlvkonna sekveneerimist, teostame kloonide kogumi järjestuste määramise. Peale
vastavat kloonide järjestuste annotatsiooni, analüüsime spetsiifilist repertuaari bioinformaatiliselt.
Kolmas projekti aasta 1.09. 2022 – 31.08. 2023. Kolmas aasta keskendub võimalike ravilahenduste
rakendamisele ja nende mõjude analüüsile. Antud osaprojektis teeme koostööd Nantes ülikooli
teadlastega, kes on teinud märkimisväärseid jõupingutusi ravilahenduste välja töötamiseks. Oleme tihedas
koostöös Nantes ülikooli ja teiste projekti osapooltega. Meie ülesanne on uurida, kuidas mõjutab anti-
CD45RC vastase antikeha või madala doosiga interleukiin IL-2 ravi rakendamine Nantes ülikoolis kliinilist
fenotüüpi kasutades AIRE-roti mudelit. Määrame selleks katseloomades autoantikehade olemasolu kui ka
nende immuunrakkude (T ja B rakkude) repertuaarid ja analüüsime need bioinformaatiliselt.
EUROOPA HARULDASTE HAIGUSTE VÕRGUSTIKU EJP RD 2019.A. TAOTLUSVOORU
GRANDILEPING NR 3-4/1165-1
Eesti Vabariik, Sotsiaalministeeriumi kaudu, registrikood 70001952, asukoht Suur-Ameerika 1,
10122 Tallinn, keda esindab Sotsiaalministeeriumi põhimääruse § 9 punkti 9 alusel kantsler Marika
Priske (edaspidi Ministeerium),
Pärt Peterson (isikukood 36604182729) Tartu Ülikooli uurimisprojekti alusel (edaspidi
Grandihoidja)
ja
Tartu Ülikool, registrikood 74001073, asukoht Ülikooli 18, 50090 Tartu, keda esindab Rektori
käskkirja no. 19 (29.12.2017) alusel Taivo Raud (edaspidi Asutus), edaspidi koos Pooled ja eraldi
Pool,
Lähtudes EJP RD raamkonsortsiumi lepingust, mis allkirjastati ministeeriumi poolt 30. septembril
2019, Tartu Ülikooli uurimisprojektist TARID (edaspidi Projekt) ja Projekti konsortsiumleppest
(edaspidi Konsortsiumileping) , mis allkirjastati Asutuse poolt 01.07.2020,
sõlmisid käesoleva grandilepingu (edaspidi Leping) alljärgnevas:
1. LEPINGU ESE
1.1. Riigieelarveline toetus summas 75 000 (seitsekümmend viis tuhat) eurot (edaspidi toetus).
1.2. Asutus kasutab toetust EJP RD 2019. a. taotlusvooru ühiskonkursil osalenud ühisprojekti
TARID „Thymic Abnormalities in Rare Immunological Diseases“, mille üks osa on Tartu
Ülikooli uurimisprojekt, läbiviimiseks. Toetuse kasutamise täpsem kirjeldus on toodud
Projektis (Lisa 4) .
1.3. Toetuse kasutamise periood on 01.09. 2020-31.08. 2023.
2. TOETUSE VÄLJAMAKSMISE AEG
2.1. Toetuse väljamakse aluseks on Projekt (Lisa 4) ja Konsortsiumileping (Lisa 5).
2.2. Ministeerium kannab toetuse Asutuse arveldusarvele vastavalt Asutuse koostatud
eelarvele (Lisa 1) järgnevalt:
2.2.1. 25 000 eurot mitte hiljem, kui 14 päeva pärast Ministeeriumi poolt Lepingu
jõustumisest teada saamist;
2.2.2. 25 000 eurot mitte hiljem, kui 14 päeva pärast I perioodi toetuse kasutamise aruande
heakskiitmist Ministeeriumi poolt vastavalt punktile 3;
2.2.3. 25 000 eurot mitte hiljem, kui 14 päeva pärast II perioodi toetuse kasutamise
aruande heakskiitmist Ministeeriumi poolt vastavalt punktile 3.
3. ARUANNETE ESITAMINE
3.1. Toetuse kasutamise aruandeperioodid on järgmised
3.1.1. I periood – 01.09.2020 – 31.08.2021
3.1.2. II periood – 01.09.2021 – 31.08.2022
3.1.3. III periood – 01.09.2022 – 31.08.2023
3.2. Grandihoidja esitab Ministeeriumile toetuse kasutamise aruande 20 (kahekümne)
tööpäeva jooksul peale iga aruandeperioodi lõppemist.
3.3. Toetuse kasutamise aruanne esitatakse lepingu Lisas 3 toodud vormil.
4. POOLTE KOHUSTUSED
4.1. Ministeerium kohustub kandma eraldatud toetuse Lepingu punktis 1.2 nimetatud
Projekti läbiviimiseks Lepingu punktis 2.2 toodud maksegraafiku aluses Asutuse
arveldusarvele.
1
4.2. Asutus kohustub:
4.2.1. andma Ministeeriumi poolt ülekantud toetuse (v.a üldkululõivu ja töötasu)
Grandihoidja käsutusse igasuguse viivituseta;
4.2.2. arvestama üldkululõivu proportsionaalselt antud Projekti raames läbiviidava
teadustöö kuludega;
4.2.3. võimaldama Grandihoidjal ja tema poolt juhitaval uurimisrühmal kasutada Projekti
täitmiseks oma infrastruktuuri;
4.2.4. vormistama Projekti töötajad (Lisa 2) tööle vastavalt töölepingu seaduses ettenähtud
nõuetele ja määrama vastavalt Grandihoidja ettepanekule Projekti palgatud
töötajatele töötasu, mille suurus on kooskõlas asutusesisese või asutusesisese
võrdluse võimatuse korral Eesti keskmise palgatasemega vastavasisulise töö eest,
võimaldama kraadiõppuritele stipendiumite maksmist Projektist;
4.2.5. sisestama Projekti andmed Eesti Teaduse Infosüsteemi (ETIS) ja avalikustama need
ühe kuu jooksul pärast Lepingu allkirjastamist;
4.2.6. informeerima Ministeeriumi kõigist asjaoludest, mis takistavad Projekti täitmist
antud Asutuses;
4.2.7. Ministeeriumi kirjalikul nõudel kandma neljateistkümne (14) päeva jooksul mitte-
sihtotstarbeliselt kasutatud või Projekti lõpus kasutamata jäänud toetuse osa
Ministeeriumi arveldusarvele;
4.2.8. võimaldama Ministeeriumil ja tema volitatud isikutel kontrollida Asutuse ja
Grandihoidja esitatud aruannete õigsust, toetuse saamise tingimuseks olevate
asjaolude paikapidavust ja toetuse kasutamise sihipärasust.
4.3. Grandihoidja kohustub:
4.3.1. kasutama talle eraldatud toetust heaperemehelikult, kokkulepitud korras ja
tingimustel;
4.3.2. esitama Ministeeriumile saadud toetuse kasutamise kohta aruande iga perioodi
kohta vastavalt Lepingu punktile 3. Aruande tähtajaks esitamata jätmise korral on
Ministeeriumil õigus peatada toetuse ülekanne kuni aruande saabumiseni ja selle
aktsepteerimiseni Ministeeriumi poolt;
4.3.3. Ministeeriumi kirjalikul nõudel esitama Lepingu punktis 3 toodud
aruandlusperioodide kestel vahearuandeid kümne (10) tööpäeva jooksul
vastavasisulise nõude saamisest;
4.3.4. Ministeeriumi kirjalikul nõudel esitama toetuse arvelt kulutuste tegemist tõendavate
algdokumentide koopiad viie (5) tööpäeva jooksul vastavasisulise nõude saamisest;
4.3.5. arvestama Ministeeriumi poolt kirjalikult tehtud märkustega ja antud juhistega,
juhistega mittenõustumisel (sh kui Grandihoidja leiab, et need ei ole kooskõlas
Lepinguga) on Grandihoidjal õigus esitada kirjalik vastuväide;
4.3.6. viivitamatult teatama Ministeeriumile:
4.3.6.1. asjaoludest, mis takistavad Grandihoidjal Lepingu täitmist;
4.3.6.2. Lepingu Lisade muutmise vajalikkusest;
4.3.6.3. Lepingu täitmisel esinevatest muudest probleemidest;
4.3.7. nimetama Ministeeriumi ja Lepingu esemes kirjeldatud tegevuse toetajana kõigis
asjakohastes trükistes (artiklid, raamatud, muud trükised jne) ja avalikel esinemistel,
kasutades võimalusel Ministeeriumi logo vastavalt valitsusasutuste ühise visuaalse
identiteedi stiilijuhistele ja EJP RD logo;
4.3.8.lõpetama Ministeeriumi või EJP RD soovil vastava sümboolika edasise kasutamise;
2
4.3.9. juhul, kui Projekti täitmisel korraldatakse inimuuringuid või loomkatseid, esitama
Ministeeriumile inimuuringute eetikakomitee või loomkatsete läbiviimise
loakomisjoni positiivse otsuse hiljemalt 10 (kümme) tööpäeva enne inimuuringute või
loomkatsete algust.
5. VASTUTUS
5.1. Pooled täidavad oma kohustusi nõuetekohaselt, mõistlikult, heas usus, hoolsalt ning
arvestades häid tavasid ja praktikat.
5.2. Pooled vastutavad oma kohustuste süülise mittetäitmise eest, kui täitmisest keeldumise
õigus ei tulene Lepingust või seadusest.
5.3. Pool teatab teistele Pooltele Lepingu rikkumisest, kirjeldades rikkumist piisavalt täpselt
kolmekümne (30) päeva jooksul arvates päevast, millal sai teada või pidi teada saama
lepingu rikkumisest.
5.4. Lepingus sätestatud kohustuste mittetäitmise või mittenõuetekohase täitmise korral on
Ministeeriumil õigus esitada toetuse saajale nõue rikkumise kõrvaldamiseks, andes
Asutusele rikkumise kõrvaldamiseks mõistliku tähtaja.
5.5. Lepingu olulise rikkumise esinemisel, sh kui Asutus ei kõrvalda rikkumist selleks antud
tähtaja jooksul või ei teata sama tähtaja jooksul rikkumist objektiivselt vabandavatest
asjaoludest, on Ministeeriumil õigus Leping ühepoolselt erakorraliselt lõpetada, teavitades
sellest vastava kirjaliku avaldusega Asutust.
5.6. Asutuse poolt Lepingust tulenevate kohustuste mittetäitmisel või mittenõuetekohasel
täitmisel on Ministeeriumil õigus nõuda toetuse saajalt leppetrahvi tasumist kuni 10%
(kümne protsendi) ulatuses toetusest ning vastavalt Ministeeriumi äranägemisele kogu
toetuse või selle osa tagastamist. Asutus tagastab toetuse (või selle osa) ja tasub
leppetrahvi 10 (kümne) tööpäeva jooksul arvates Ministeeriumi vastavasisulise nõude
kättesaamisest.
5.7. Lepingust tulenevate kohustuste täitmata jätmise või mittekohase täitmisega teisele
Poolele tekitatud otsese varalise kahju eest kannavad Pooled täielikku vastutust selle kahju
täies ulatuses.
5.8. Lepingust tulenevate kohustuste mittetäitmist või mittenõuetekohast täitmist ei loeta
Lepingu rikkumiseks, kui selle põhjuseks oli vääramatu jõud. Vääramatu jõuna käsitavad
pooled võlaõigusseaduse § 103 lõikes 2 nimetatud asjaolusid. Pool, kelle tegevus
lepingujärgsete kohustuste täitmisel on takistatud vääramatu jõu asjaolude tõttu, on
kohustatud sellest kohe teisele poolele kirjalikku taasesitamist võimaldavas vormis
teatama. Vääramatu jõu asjaolude ilmnemisel pikeneb Lepingu lõpptähtaeg nimetatud
asjaolude esinemise perioodi võrra. Pool peab vääramatu jõu asjaolude äralangemisel
asuma Lepingut täitma. Kui vääramatu jõu asjaolude tõttu on poole Lepingust tulenevate
kohustuste täitmine takistatud enam kui 60 (kuuskümmend) kalendripäeva järjest, võib
kumbki Pool Lepingu lõpetada.
5.9. Pooled ei vastuta kohustuste täitmata jätmise eest, kui Lepingu mittekohase täitmise
põhjustab teine Pool oma Lepingust tulenevate kohustuste täitmata jätmisega.
6. VAIDLUSTE LAHENDAMINE
6.1. Lepingust tulenevad vaidlused lahendatakse eelkõige vastastikusel mõistmisel põhinevate
ja avalikke huve arvestavate läbirääkimiste teel.
6.2. Kui läbirääkimised ei anna tulemusi, lahendatakse vaidlus Harju Maakohtus.
7. LEPINGU KEHTIVUS JA LEPINGUST TAGANEMINE
7.1. Leping jõustub hetkel, kui Lepingu pooled on sellele alla kirjutanud, ja kehtib, kuni pooled
on kõik Lepingust tulenevad kohustused täitnud.
3
7.2. Pooltel on õigus Leping omavahelisel kirjalikul kokkuleppel igal ajal lõpetada.
7.3. Pooltel on õigus Lepingust ühepoolselt taganeda, teatades vastavast soovist teisele
poolele vähemalt kolmkümmend (30) päeva ette.
7.4. Pool võib Lepingust taganeda, kui teine Pool on Lepingust tulenevat kohustust oluliselt
rikkunud ning ei ole seda kõrvaldanud mõistliku tähtaja jooksul.
7.5. Lepingu lõpetamisel punktides 7.2-7.5 juhtudel tagastab Asutus kasutamata jäänud
toetuse Ministeeriumile 10 (kümne) tööpäeva jooksul peale Lepingu lõppemist.
7.6. Lepingu lõppemine ei vabasta Pooli lepingu olemusest ja teise Poole huvist tulenevatest
kohustustest.
8. Volitatud esindajad
8.1. Ministeeriumi esindajaks Lepingu täitmisega seotud küsimustes on: Mari Teesalu, tel. 626
9715, e-post
[email protected], või teda asendav isik.
8.2. Asutuse esindajaks Lepingu täitmisega seotud küsimustes on: Grandihoidja Pärt Peterson,
tel 53443855, e-posti aadress
[email protected]
9. LEPINGU DOKUMENDID
9.1. Leping koosneb käesolevast Lepingust koos selle Lisadega ja pärast Lepingu sõlmimist
sellest tehtud muudatustest, mis vormistatakse Lepingu lisana, mis on Lepingu
lahutamatuteks osadeks ning moodustavad koos Lepinguga ühtse tervikliku Poolte vahel.
9.2. Lepingule on allkirjastamise hetkel lisatud alljärgnevad Lisad:
9.2.1. Lisa 1 – Projekti eelarve aastate kaupa
9.2.2. Lisa 2 – Projekti täitjate nimekiri;
9.2.3. Lisa 3 – Toetuse kasutamise aruande vorm;
9.2.4. Lisa 4 – Tartu Ülikooli uurimisprojekt TARID;
9.2.5. Lisa 5 – TARID projekti konsortsiumileping.
9.3. Lepingu osaks on lisaks käesolevatele Lepingule ja selle Lisadele muud kokkulepped, mis
sõlmitakse Lepingu sõlmimise ajal või pärast Lepingu sõlmimist ning milles sätestatakse
seosed Lepinguga. Pooled kinnitavad, et sellised kokkulepped moodustavad koos
Lepinguga ühtse tervikliku kokkuleppe Poolte vahel.
10. LÕPPSÄTTED
10.1. Lepinguga reguleerimata küsimustes lähtuvad pooled Eesti Vabariigis kehtivatest
õigusaktidest.
10.2. Leping on koostatud eesti keeles, elektroonselt ja allkirjastatud digitaalselt.
11. POOLTE REKVISIIDID JA ALLKIRJAD
11.1. Ministeerium: Sotsiaalministeerium
Aadress: Suur-Ameerika 1, Tallinn
Tel: 626 9301
Faks: 626 9209
E-post:
[email protected]
11.2. Grandihoidja: Pärt Peterson
Aadress: Ravila 19, Biomeedikum, Tartu Ülikool
Tel: 53443855
E-post:
[email protected]
4
11.3. Asutus: Tartu Ülikool
Aadress: Lossi 3, 51003 Tartu
Tel: 737 6193
E-post:
[email protected]
Arveldusarve: EE281010102000234007
/allkirjastatud digitaalselt/ /allkirjastatud digitaalselt/ /allkirjastatud digitaalselt/
5
Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr 3-4/1165-1 Lisa 1
Pojekti eelarve aastate kaupa
01.09.2020 – 01.09.2021 – 01.09.2022 –
Kogueelarve
31.08.2021 31.08.2022 31.08.2023
Töötasud ja sellega seotud
14 100 14 100 14 100 42 300
maksud (k.a stipendiumid)
Põhivara - - -
Lähetused 400 400 400 1200
Muud kulud (töömaterjalid
5500 5500 5500 16 500
ja alltöövõtt)
Üldkululõiv 5000 5000 5000 15 000
Kokku 25 000 25 000 25 000 75 000
6
Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr 3-4/1165-1 Lisa 2
Projekti põhitäitjate ja projekti täitmisele kaasatud kraadiõppurite nimekiri.
Perekonnanimi Eesnimi Ametikoht Koormus Kavandatud töötasu
projektis (koos maksudega)
või stipendium
Peterson Pärt Professor 0.2 -
Laan Martti Dotsent 0.2 -
Sein Hanna Laborispetsialist 0.5 31,500
Stoljar Artur Doktorant 0.5 10,800
Kisand Kai Juhtivteadur 0.1 -
Töötasu kokku 42,300
7
Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr 3-4/1165-1 Lisa 3
SOTSIAALMINISTEERIUM
Suur-Ameerika 1
10122 Tallinn
TOETUSE KASUTAMISE ARUANNE 20__. a kohta
Asutus: Tartu Ülikool
Grandihoidja: Pärt Peterson
Projekti nimetus: Tartu Ülikooli projekt TARID
Kulude aruanne:
Kogueelarve Täitmine Täitmine projekti Täidetud kogu
20_ algusest eelarvest (%)
Töötasud ja sellega seotud
maksud (k.a stipendiumid)
Põhivara
Lähetused
Muud kulud (töömaterjalid ja
alltöövõtt)
Üldkululõiv
Kokku
20__. a tegevuste kirjeldus (vähemalt 4000 tähemärki):
______________________________ _________________________________________
Grandihoidja (allkiri, kuupäev) Asutuse esindaja (nimi, allkiri, kuupäev)
8